Sumitomo Pharma Co., Ltd.
DNPUF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $283,570,505 | $156,639,605 | $336,428,709 | $493,951,868 |
| - Cash | $23,116,000 | $29,047,000 | $143,478,000 | $202,984,000 |
| + Debt | $305,422,000 | $427,864,000 | $334,716,000 | $269,048,000 |
| Enterprise Value | $565,876,505 | $555,456,605 | $527,666,709 | $560,015,868 |
| Revenue | $398,832,000 | $314,558,000 | $555,544,000 | $560,035,000 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Gross Profit | $245,395,000 | $187,981,000 | $376,625,000 | $402,908,000 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| EBITDA | $38,585,000 | -$317,371,000 | -$3,498,000 | $98,315,000 |
| % Margin | 9.7% | -100.9% | -0.6% | 17.6% |
| Net Income | $23,634,000 | -$314,969,000 | -$74,512,000 | $56,413,000 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| Operating Cash Flow | $16,500,000 | -$241,893,000 | $11,937,000 | $31,239,000 |
| Capital Expenditures | -$13,030,000 | -$15,730,000 | -$12,742,000 | -$13,494,000 |
| Free Cash Flow | $3,470,000 | -$257,623,000 | -$805,000 | $17,745,000 |